The DOI matches its Crossref record.
Hepatotoxicity after introduction of highly active antiretroviral therapy
Abstract
The life expectancy of HIV-infected patients has dramatically changed in the last 2 years since the introduction of triple drug combinations, mainly those including protease inhibitors [1]. However, issues on compliance and adverse effects have now became evident as a limiting cause of benefit in a substantial proportion of individuals [2]. Amongst others, liver toxicity is now one of the leading reasons for withdrawn treatment [3–6]. We analysed the first 187 patients who began highly active antiretroviral therapy (HAART) in a reference centre for HIV/AIDS located in Madrid. Examination of liver function was made at baseline and after 1 month of starting treatment. Criteria for liver injury were established when (i) both alanine and aspartate aminotransferase levels increased at least twofold with respect to baseline values; (ii) bilirubin levels were raised above 2.5 g/l; and (iii) development of clinical hepatic failure (ascites, encephalopathy, jaundice) occurred. The mean age of the study population was 37.5 ± 8 years, and 157 (84%) were men. Study subjects had acquired HIV infection through injecting drug use (48%), homosexual contacts (37.4%), and heterosexual relationships (14.5%). Most (84.1%) had received nucleoside analogues, and had detectable levels of HIV plasma viraemia or low CD4 cell counts when they began HAART. Protease inhibitors were administered at different rates: indinavir (73.8%), saquinavir (10.2%), and ritonavir (7.5%). Moreover, the combination of ritonavir plus saquinavir was administered in 8.6% of patients. The most frequent nucleoside combinations were as follows: stavudine plus lamivudine (66.3%), zidovudine plus lamivudine (11.8%), stavudine plus didanosine (9.6%), zidovudine plus zalcitabine (5.3%), and zidovudine plus didanosine (1.6%). A significant increase in transaminases (more than twofold) was recognized in 26 (13.9%) patients, whereas bilirubin increases above 2.5 g/l were seen in seven (3.7%) individuals. Eleven (5.9%) subjects needed to stop the medication because of either hepatic cytolysis (nine patient), or hyperbilirubinaemia (one patient), or both (one patient). Four (2.1%) individuals developed clinical hepatic decompensation, and one of them died. This patient was receiving stavudine, lamivudine plus indinavir, and he had been diagnosed with multiple chronic hepatitis (hepatitis B, C and D), although this was his first episode of clinical liver failure. In injecting drug users (IDU), baseline values of alanine and aspartate aminotransferases were significantly higher (P < 0.001) than in patients from other risk categories. Most likely, this reflects the high prevalence of chronic hepatitis C virus (HCV) infection amongst IDU [7]. It is noteworthy that significant increases in bilirubin (> 0.5 g/l) occurred more frequently in IDU (31 out of 86; 36%) than in the other patients (25 out of 93; 26.9%; P < 0.001). Similarly, transaminase values raised more than twofold in 17 (19.8%) out of 86 IDU, but in only eight (8.6%) of the remaining 93 subjects (P = 0.08). Patients receiving indinavir developed hyperbilirubinaemia more frequently (56 out of 138; 40.6%) than subjects receiving other protease inhibitors (three out of 49; 6.1%; P < 0.001). Any nucleosides analogue was more hepatotoxic than the others. Chronic HCV infection was an independent predictor of hepatotoxicity: transaminase levels increased more than twofold in 16 (21.1%) out of 76 subjects with chronic HCV infection, but only in four (7.4%) out of 54 without chronic HCV (P = 0.03). In contrast, no association was found between development of significant hyperbilirubinaemia and chronic HCV (P = 0.2). In conclusion, hepatotoxicity is frequently seen in patients under HAART, and can force the withdrawal of antiviral treatment in a significant proportion of patients, occasionally resulting in fatal outcome. The development of cytolytic injury is particularly common in subjects with chronic HCV, and meanwhile cholestasis seems to be more frequent in patients under indinavir-containing regimens. Since most HIV-positive IDU are chronically infected with HCV, clinicians must be alert on the hepatic complications that can follow the introduction of HAART in these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection
Paterson, D. L., Swindells, S., Mohr, J., Brester, M., Vergis, E. N., Squier, C., Wagener, M. M., & Singh, N. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-1-200007040-00004 · Cited by 3,289
Bica, I., McGovern, B., Dhar, R., Stone, D., McGowan, K., Scheib, R., & Snydman, D. R. (2001) · Clinical Infectious Diseases · doi:10.1086/318501 · Cited by 974
Sulkowski, M. S. (2000) · JAMA · doi:10.1001/jama.283.1.74 · Cited by 950
Sociodemographic and psychological variables influencing adherence to antiretroviral therapy
Gordillo, V., del Amo, J., Soriano, V., & González-Lahoz, J. (1999) · AIDS · doi:10.1097/00002030-199909100-00021 · Cited by 658
Self-citationMasur, P. B. H., Kaplan, J. E., & Holmes, K. K. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-5_part_2-200209031-00002 · Cited by 567
Metadata
- Authors
- Rodríguez-Rosado, R., García-Samaniego, J., & Soriano, V
- Venue
- AIDS
- Published
- 1998-07
- Volume
- 12
- Issue
- 10
- Pages
- 1256
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2060137807
- Cited by
- 190
- References
- 0
- FWCI
- 14.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepatotoxicity after introduction of highly active antiretroviral therapy. https://app.cochat.ai/papers/10.1097/00002030-199810000-00025
- The paper
- Rodríguez-Rosado, R., García-Samaniego, J., & Soriano, V. (1998). Hepatotoxicity after introduction of highly active antiretroviral therapy. AIDS. https://doi.org/10.1097/00002030-199810000-00025
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.